Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial
Primary result · Percentage change in body weightResult — go to the resultEstimated treatment difference −13.07 percentage points 95% CI −15.61 to −10.52Authors' conclusion
In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without T2D, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction in body weight compared with placebo, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist class.
Study context
- Population
- East Asian adults (Japan and South Korea) with body mass index (BMI) ≥27.0 and ≥2 related complications or BMI ≥35.0 and ≥1 related complication, with or without T2D; mean age 49 years, 43.3% female, 25.4% with T2Drandomized 2:1
- Participants
- 201 adults
- Comparison
- Once-daily oral semaglutide 50 mg vs placebo, plus lifestyle recommendations
- Semaglutiden = 134
- Placebon = 67reference
- Primary endpoint
- Coprimary: percentage change in body weight from baseline; proportion achieving ≥5% body weight reduction
- Follow-up
- 68 weeks
Methodological detailsmulticenter, double-blind, placebo-controlled, phase 3a, Conducted November 2021 to September 2023 in Japan and South Korea; 68 weeks plus 7 weeks follow-up
- Multicenter
- Double-blind
- Placebo-controlled
- Phase 3a
- Conducted November 2021 to September 2023 in Japan and South Korea; 68 weeks plus 7 weeks follow-up
Primary result
Percentage change in body weight
Estimated treatment difference
−13.07 percentage points
95% CI −15.61 to −10.52
P < 0.001
Change by group
Semaglutide
−14.3
mean · SE 0.8 · %
Placebo
−1.3
mean · SE 1.1 · %
Semaglutidevs Placebo
estimated treatment difference −13.07 percentage points (95% CI −15.61 to −10.52); P < 0.001
As reported in the abstract
Further findings
| Outcome | Semaglutide | Placebo | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Coprimary: ≥5% body weight reduction | 84.3% | 17.2% | 23.00 (10.28–51.42) | P < 0.001 | |
| 0.050.21520Odds ratio (log scale) |
Safety
Gastrointestinal adverse events
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Adverse events leading to treatment discontinuation | 4.5% | — not stated in the abstract |
— not stated in the abstract
Original publication
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. JAMA Intern Med. Published 1 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →